Glasdegib Terminated Phase 2 Trials for Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02226172Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib